ArticleIranian journal of microbiology2011
Susceptibility of clinical Candida species isolates to antifungal agents by E-test, Southern Iran: A five year study.
Article in Iranian journal of microbiology, 2011. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 31 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
31 citing papers in PubMed, 70 citations in OpenAlex.
- Phenotypic and Molecular Assessment ofPathogens (Basel, Switzerland) · 2026Article
- Molecular Identification and Antifungal Susceptibility Patterns of Candida Species in Pediatric Patients at Tabriz Children's Hospital.BioMed research international · 2026Article
- Antifungal and Antioxidant Activity of Thiourea Derivatives Against NosocomialMolecules (Basel, Switzerland) · 2025Article
- Candidemia chronicles: Retrospective analysis of candidemia epidemiology, species distribution, and antifungal susceptibility patterns in Bahrain.World journal of virology · 2024Article
- Fighting Emerging Caspofungin-ResistantAntibiotics (Basel, Switzerland) · 2024Article
- Mycological evaluation of frozen meat with special reference to yeasts.Veterinary world · 2023Article
- Antifungal Resistance of ClinicalIranian journal of public health · 2023Review
- Antifungal resistance, combinations and pipeline: oh my!Drugs in context · 2023Review
- Vaginal and oral use of probiotics as adjunctive therapy to fluconazole in patients with vulvovaginal candidiasis: A clinical trial on Iranian women.Current medical mycology · 2021Article
- Treating (Recurrent) Vulvovaginal Candidiasis with Medical-Grade Honey-Concepts and Practical Considerations.Journal of fungi (Basel, Switzerland) · 2021Review
- Synthesis, Antibacterial and Antifungal Activity of New 3-Aryl-5Molecules (Basel, Switzerland) · 2021Article
- Impact of antifungal stewardship interventions on the susceptibility of colonized Candida species in pediatric patients with malignancy.Scientific reports · 2021Article
- Article
- Amphotericin B and Other Polyenes-Discovery, Clinical Use, Mode of Action and Drug Resistance.Journal of fungi (Basel, Switzerland) · 2020Review
- Distribution of Candida albicans and non-albicans Candida species isolated in different clinical samples and their in vitro antifungal suscetibity profile in Ethiopia.BMC infectious diseases · 2020Article
- Article
- Candiduria; a review article with specific data from Iran.Turkish journal of urology · 2018Review
- Catheter-related candidemia and identification of causativeCurrent medical mycology · 2018Article
- Caspofungin MIC Distribution amongst Commonly IsolatedJournal of clinical and diagnostic research : JCDR · 2016Article
- Antifungal Susceptibility Analysis of Clinical Isolates of Candida parapsilosis in Iran.Iranian journal of public health · 2016Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
BACKGROUND AND
objectivesThe incidence of fungal infections in immunocompromised patients, especially by Candida species, has increased in recent years. This study was designed to identify Candida species and determine antifungal susceptibility patterns of 595 yeast strains isolated from various clinical specimens. MATERIAL AND
methodsIdentification of the isolates were determined by the API 20 C AUX kit and antifungal susceptibilities of the species to fluconazole, amphotericin B, ketoconazole, itraconazole, voriconazole, and caspofungin were determined by the agar-based E-test method.
resultsCandida albicans (48%) was the most frequently isolated species, followed by Candida kruzei (16.1%), Candida glabrata (13.5%), Candida kefyr (7.4%), Candida parapsilosis (4.8%), Candida tropicalis (1.7%) and other species (8.5%). Resistance varies depending on the species and the respective antifungal agents. Comparing the MIC90 for all the strains, the lower MIC90 was observed for caspofungin (0.5 µg/ml). The MIC90 for all Candida species were 64 µg/ml for fluconazole, 0.75 µg/ml for amphotericin B, 4 µg/ml for ketoconazole, 4 µg/ml for itraconazole, and 2 µg/ml for voriconazole.
conclusionsSpecies definition and determination of antifungal susceptibility patterns are advised for the proper management and treatment of patients at risk for systemic candidiasis. Resistance to antifungal agents is an alarming sign for the emerging common nosocomial fungal infections.
Indexed as
Identifiers
22530086PMC3330181W2103684042What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.